Naweed I Chowdhury1, Jess C Mace1, Timothy L Smith1, Luke Rudmik2. 1. Department of Otolaryngology-Head and Neck Surgery, Division of Rhinology, Oregon Health and Science University, Portland, Oregon, U.S.A. 2. Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Calgary, Calgary, Alberta, Canada.
Abstract
OBJECTIVES/HYPOTHESIS: Previous studies have shown declines in productivity due to chronic rhinosinusitis (CRS) are correlated with disease-specific quality-of-life (QOL) measures. However, it is unclear which symptom domains contribute primarily to productivity loss. This investigation sought to assess the association between CRS-specific QOL subdomain impairment and productivity loss. STUDY DESIGN: Prospective, multi-institutional, observational cohort study. METHODS: There were 198 patients with refractory CRS enrolled between August 2012 and June 2015. Baseline QOL measures were obtained across five subdomains of the 22-item SinoNasal Outcome Test (SNOT-22). Lost productivity time was determined from patient-reported measures of annual absenteeism, presenteeism, and lost leisure time, and then monetized using annual daily wage rates from the 2012 US National Census and 2013 Department of Labor statistics. RESULTS: Productivity losses correlated with impairments in both SNOT-22 psychological dysfunction (Spearman correlation coefficient [Rs] = 0.428, P < .001), and sleep dysfunction domain scores (Rs = 0.355, P < .001). Higher SNOT-22 total scores also significantly correlated with increased monetized productivity losses (Rs = 0.366, P < .001). The mean annual productivity cost was $11,820/patient, whereas patients with comorbid immunodeficiency ($23,285/patient), tobacco use ($23,195/patient), and steroid dependency ($18,910/patient) reported higher than average annual productivity costs. Multivariate linear regression found maximum annual productivity costs in adjusted psychological ($13,300/patient, P < .001) and sleep dysfunction ($9,275/patient, P < .001) domains. CONCLUSIONS: Impairments in sleep and psychological SNOT-22 domains correlate with productivity losses. Patients with comorbid immunodeficiency, smoking, and steroid dependency had higher than average productivity losses. Targeted management of psychological and sleep dysfunction in combination with standard symptom control may improve patient-centered care and reduce the annual economic burden of CRS. LEVEL OF EVIDENCE: 2c. Laryngoscope, 128:23-30, 2018.
OBJECTIVES/HYPOTHESIS: Previous studies have shown declines in productivity due to chronic rhinosinusitis (CRS) are correlated with disease-specific quality-of-life (QOL) measures. However, it is unclear which symptom domains contribute primarily to productivity loss. This investigation sought to assess the association between CRS-specific QOL subdomain impairment and productivity loss. STUDY DESIGN: Prospective, multi-institutional, observational cohort study. METHODS: There were 198 patients with refractory CRS enrolled between August 2012 and June 2015. Baseline QOL measures were obtained across five subdomains of the 22-item SinoNasal Outcome Test (SNOT-22). Lost productivity time was determined from patient-reported measures of annual absenteeism, presenteeism, and lost leisure time, and then monetized using annual daily wage rates from the 2012 US National Census and 2013 Department of Labor statistics. RESULTS: Productivity losses correlated with impairments in both SNOT-22 psychological dysfunction (Spearman correlation coefficient [Rs] = 0.428, P < .001), and sleep dysfunction domain scores (Rs = 0.355, P < .001). Higher SNOT-22 total scores also significantly correlated with increased monetized productivity losses (Rs = 0.366, P < .001). The mean annual productivity cost was $11,820/patient, whereas patients with comorbid immunodeficiency ($23,285/patient), tobacco use ($23,195/patient), and steroid dependency ($18,910/patient) reported higher than average annual productivity costs. Multivariate linear regression found maximum annual productivity costs in adjusted psychological ($13,300/patient, P < .001) and sleep dysfunction ($9,275/patient, P < .001) domains. CONCLUSIONS:Impairments in sleep and psychological SNOT-22 domains correlate with productivity losses. Patients with comorbid immunodeficiency, smoking, and steroid dependency had higher than average productivity losses. Targeted management of psychological and sleep dysfunction in combination with standard symptom control may improve patient-centered care and reduce the annual economic burden of CRS. LEVEL OF EVIDENCE: 2c. Laryngoscope, 128:23-30, 2018.
Authors: Ron Z Goetzel; Stacey R Long; Ronald J Ozminkowski; Kevin Hawkins; Shaohung Wang; Wendy Lynch Journal: J Occup Environ Med Date: 2004-04 Impact factor: 2.162
Authors: Adam S DeConde; Jess C Mace; Joshua M Levy; Luke Rudmik; Jeremiah A Alt; Timothy L Smith Journal: Laryngoscope Date: 2016-11-12 Impact factor: 3.325
Authors: Joshua M Levy; Jess C Mace; Adam S DeConde; Toby O Steele; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2016-04-15 Impact factor: 3.858
Authors: Timothy L Smith; Jess C Mace; Luke Rudmik; Rodney J Schlosser; Peter H Hwang; Jeremiah A Alt; Zachary M Soler Journal: Laryngoscope Date: 2016-06-14 Impact factor: 3.325
Authors: Edward El Rassi; Jess C Mace; Toby O Steele; Jeremiah A Alt; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2015-12-17 Impact factor: 3.858
Authors: Daniel M Beswick; Jess C Mace; Luke Rudmik; Zachary M Soler; Adam S DeConde; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2018-07-28 Impact factor: 3.858
Authors: Naweed I Chowdhury; Timothy L Smith; Rakesh K Chandra; Justin H Turner Journal: Int Forum Allergy Rhinol Date: 2018-08-11 Impact factor: 3.858
Authors: Jordan R Kuiper; Annemarie G Hirsch; Karen Bandeen-Roche; Agnes S Sundaresan; Bruce K Tan; Robert C Kern; Robert P Schleimer; Brian S Schwartz Journal: J Occup Environ Med Date: 2019-08 Impact factor: 2.162
Authors: Daniel M Beswick; Jess C Mace; Zachary M Soler; Luke Rudmik; Jeremiah A Alt; Kristine A Smith; Kara Y Detwiller; Vijay R Ramakrishnan; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2019-06-27 Impact factor: 3.858
Authors: Naweed I Chowdhury; Jess C Mace; Todd E Bodner; Jeremiah A Alt; Adam S Deconde; Joshua M Levy; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2017-10-20 Impact factor: 3.858
Authors: Naweed I Chowdhury; Jess C Mace; Todd E Bodner; Jeremiah A Alt; Adam S Deconde; Joshua M Levy; Timothy L Smith Journal: Laryngoscope Date: 2018-09-12 Impact factor: 3.325
Authors: Alma Aurelia Maniu; Maria Ida Perde-Schrepler; Corina Bianca Tatomir; Mihai Ionuţ Tănase; Maximilian George Dindelegan; Vlad Andrei Budu; Gheorghe Doinel Rădeanu; Marcel Cosgarea; Carmen Aurelia Mogoantă Journal: Rom J Morphol Embryol Date: 2020 Apr-Jun Impact factor: 1.033
Authors: Robert Naclerio; Fuad Baroody; Claus Bachert; Benjamin Bleier; Larry Borish; Erica Brittain; Geoffrey Chupp; Anat Fisher; Wytske Fokkens; Philippe Gevaert; David Kennedy; Jean Kim; Tanya M Laidlaw; Jake J Lee; Jay F Piccirillo; Jayant M Pinto; Lauren T Roland; Robert P Schleimer; Rodney J Schlosser; Julie M Schwaninger; Timothy L Smith; Bruce K Tan; Ming Tan; Elina Toskala; Sally Wenzel; Alkis Togias Journal: J Allergy Clin Immunol Pract Date: 2020-03-04